

“Translation of genomics into routine cardiological practice”



ESC Cardiovascular Round Table



ESC


European Society
of Cardiology





FDA's Marks Supports Accelerated Approval for Gene Therapies

Published: Mar 21, 2023 | By Rosemary Scott



- The new **ESC Council on Cardiovascular Genomics** is a multi-stakeholder body whose mission to encourage **research, education** and the sharing of **genomic knowledge**.



Join us

& ENJOY MEMBERSHIP BENEFITS



NEWSLETTER



MEMBER DIRECTORY



NETWORKING

www.escardio.org/genomics

FREE
Membership

CRT Workshop

23-24 March 2023

Marriott Munich Airport Hotel

“Translation of genomics into routine cardiological practice”

Chairpersons

Prof. Stefanie Dimmeler (ESC), Prof. Perry Elliott (ESC),
Dr Leticia Ferri (BMS), Dr Paul Nioi (Alynlam), Dr Chris O’Donnell (Novartis)



“Translation of genomics into routine cardiological practice”

1. Current state of the art in genetic diagnostics and therapy.
2. Describe the current and future barriers to translation.
3. Propose an action plan to accelerate into routine care



Breakout 1 **EXEMPLARS OF TRANSLATION INTO CLINICAL PRACTICE AND LESSONS LEARNT**

1. What do we mean by precision diagnostics and treatment?
2. What are the characteristics of a successful CV precision therapy?
3. How do we collectively prioritise and implement new treatments?

Breakout 2 **CURRENT STATE OF THE ART: CHALLENGES FOR GENE THERAPY**

1. What are the main technical/biological barriers to overcome?
2. What can we do collectively to accelerate translation to patients?

Breakout 3 **DIAGNOSTICS: POLYGENIC RISK SCORES**

1. How do we prioritize diseases for gene therapy?
2. What are meaningful end-points in gene trials?
3. What should professional societies/organizations be doing to prepare for precision diagnostics and therapy in CVD?

Inequity, sex, healthcare systems, socioeconomic factors that might influence precision diagnostics and treatment?

ZOOM PARTICIPANTS: fbakry@escardio.org

